A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat or Placebo When co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia.

Trial Profile

A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat or Placebo When co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Lapaquistat (Primary)
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2009 Actual patient number (649) added as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Planned end date changed from 1 Feb 2007 to 1 Mar 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top